© 2026 Aureon Bioscience
RETATRUTIDE 20mg - Wholesale
Sale price
$150.00
Regular price
$350.00
Skip to product information
RETATRUTIDE 20mg - Wholesale
Retatrutide:
Product Specifications
- Name: Retatrutide
- Synonyms: LY3437943
- Purity: ≥99% (independent third-party HPLC/MS)
- Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
- Molecular Weight: ~4,731.33 g/mol
- Additives: None (mannitol-free)
- Intended use: In-vitro/ex-vivo research only
Storage & Stability
- Unreconstituted: Store dry and light-protected
- After reconstitution: 2–8 °C; aliquot to reduce freeze-thaw cycles
- Shelf life: 4 years
Mechanism of Action:
Retatrutide is a triple-receptor agonist that activates three hormone receptors involved in metabolism and appetite:
-
GLP-1 (glucagon-like peptide-1)
-
GIP (glucose-dependent insulinotropic polypeptide)
-
Glucagon
This “triple” activity aims to reduce appetite, regulate blood sugar, increase energy expenditure, and enhance fat burning more effectively than drugs targeting only one or two of these pathways.
Clinical Effects
-
In late-stage trials, retatrutide has produced substantial weight loss — up to about 28.7 % of body weight on average over ~68 weeks, with many achieving 30 % or more.
-
Significant improvements in joint-pain and physical function have also been observed in obese patients with osteoarthritis.
-
Earlier studies showed weight reductions of roughly 22–24 % over 48 weeks.
-
The drug also shows effects on blood glucose control and metabolic markers relevant to type 2 diabetes and fatty liver disease, though research continues.
Administration
Retatrutide is delivered by a once-weekly subcutaneous injection in clinical settings.
Side Effects and Safety
Common side effects reported in trials are primarily gastrointestinal, including nausea, vomiting, diarrhea, and constipation. These effects are dose-related and often mild to moderate, and some participants discontinue therapy due to intolerance.
Other observed effects include transient increases in heart rate.
Potential Uses Under Study:
-
Obesity management and significant weight loss
-
Type 2 diabetes treatment via improved glycemic control
-
Metabolic dysfunction–associated liver disease through reduction in liver fat
Research continues to confirm long-term efficacy and safety across populations.
Properties
1. Basic Information
2. Structural Properties Peptide Nature: Linear peptide with C18 fatty diacid conjugation via linker for albumin binding
Secondary Structure: Adopts α-helical conformation in the receptor-binding region
Hydrophobicity: Moderately hydrophobic; fatty acid conjugation increases lipophilicity
Charge: Net negative to neutral charge at physiological pH
3. Solubility
4. Stability Thermal Stability: Sensitive to elevated temperatures; refrigerate after reconstitution
Proteolytic Stability: Aib substitution confers DPP-IV resistance; half-life ~6 days
Storage: Store lyophilized at −20°C; reconstituted stable up to 30 days at 2–8°C
5. Chemical Reactivity Fatty acid conjugation via lysine side chain enables non-covalent albumin binding
Aib substitutions at key positions prevent enzymatic degradation
Peptide bonds are stable at neutral pH; susceptible to hydrolysis under extreme conditions
Oxidation-sensitive residues protected through sequence engineering
6. Other Properties
- Name: Retatrutide (LY3437943)
- Type: Triple agonist peptide (GIP/GLP-1/Glucagon receptor)
- Length: 36 amino acids
- Sequence: Modified peptide based on GIP scaffold with GLP-1 and glucagon receptor activity
- Molecular Weight: ~4.7 kDa with fatty acid conjugation
- Formula: Complex conjugated peptide; exact formula proprietary to Eli Lilly
2. Structural Properties Peptide Nature: Linear peptide with C18 fatty diacid conjugation via linker for albumin binding
Secondary Structure: Adopts α-helical conformation in the receptor-binding region
Hydrophobicity: Moderately hydrophobic; fatty acid conjugation increases lipophilicity
Charge: Net negative to neutral charge at physiological pH
3. Solubility
- Soluble in aqueous buffers; fatty acid chain reduces aqueous solubility slightly
- Formulated for subcutaneous injection at neutral pH
- Supplied as lyophilized powder for reconstitution
4. Stability Thermal Stability: Sensitive to elevated temperatures; refrigerate after reconstitution
Proteolytic Stability: Aib substitution confers DPP-IV resistance; half-life ~6 days
Storage: Store lyophilized at −20°C; reconstituted stable up to 30 days at 2–8°C
5. Chemical Reactivity Fatty acid conjugation via lysine side chain enables non-covalent albumin binding
Aib substitutions at key positions prevent enzymatic degradation
Peptide bonds are stable at neutral pH; susceptible to hydrolysis under extreme conditions
Oxidation-sensitive residues protected through sequence engineering
6. Other Properties
- Triple agonist activity: Simultaneous activation of GIP, GLP-1, and glucagon receptors
- Extended half-life: ~6 days enabling once-weekly dosing in research models
- Bioactive: Studied in preclinical models for effects on energy expenditure and body composition
Description
Retatrutide is a synthetic triple receptor agonist peptide and has been described in the scientific literature as a molecule designed to interact with GIP, GLP-1, and glucagon receptors simultaneously. Publications referencing Retatrutide discuss it in the context of incretin signaling and multi-receptor pharmacology within experimental systems.
Reports involving Retatrutide describe its binding characteristics at GIP, GLP-1, and glucagon receptors under defined experimental conditions. Observations of receptor activation and associated downstream signaling components are limited to non-clinical research settings and are reported as descriptive findings within cellular and animal model studies.
All references to Retatrutide are confined to mechanistic and observational research contexts and do not extend beyond laboratory-based investigation.
In the scientific literature, Retatrutide has been referenced in non-clinical and early-phase clinical research involving receptor binding assays and animal model studies. These publications describe experimental contexts in which molecular interactions, signaling components, and pathway-associated markers were observed and recorded.
Reported research contexts include examination of:
- GIP, GLP-1, and glucagon receptor co-activation dynamics in experimental models
- Insulin secretion-associated molecular markers observed in controlled studies
- Energy expenditure-related signaling components evaluated in animal systems
- Body composition-associated molecular markers in preclinical model systems
- Glucose homeostasis pathway components measured under experimental conditions
All reported applications are confined to descriptive investigation within controlled laboratory research environments.
Mechanistic discussions in preclinical publications describe Retatrutide in relation to multi-receptor signaling networks associated with metabolic regulation. Additional references describe observations of extended circulating half-life attributed to fatty acid conjugation enabling albumin binding. These descriptions are limited to molecular and biochemical observations within experimental systems.
Retatrutide is supplied as a research-grade peptide material. Identity and composition have been reported as characterized using analytical techniques commonly applied to peptide research materials, including chromatographic and mass spectrometric methods. Individual laboratories determine handling, storage, and analytical verification parameters in accordance with internal research protocols.
COA
Storage
All of our products are manufactured using the Lyophilization (Freeze Drying) process, which ensures that our products remain 100% stable for shipping for up to 3-4 months. Once the peptides are reconstituted (mixed with bacteriostatic water), they must be stored in the fridge to maintain stability. After reconstitution, the peptides will remain stable for up to 30 days.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you're ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4°C (39°F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
For longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80°C (-112°F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide's stability.
Lyophilization is a unique dehydration process, also known as cryodesiccation, where the peptides are frozen and then subjected to low pressure. This causes the water in the peptide vial to sublimate directly from solid to gas, leaving behind a stable, crystalline white structure known as lyophilized peptide. The puffy white powder can be stored at room temperature until you're ready to reconstitute it with bacteriostatic water.
Once peptides have been received, it is imperative that they are kept cold and away from light. If the peptides will be used immediately, or in the next several days, weeks or months, short-term refrigeration under 4°C (39°F) is generally acceptable. Lyophilized peptides are usually stable at room temperatures for several weeks or more, so if they will be utilized within weeks or months such storage is typically adequate.
For longer term storage (several months to years) it is more preferable to store peptides in a freezer at -80°C (-112°F). When storing peptides for months or even years, freezing is optimal in order to preserve the peptide's stability.
